Abstract:Rapid developments in Regenerative Medicine and Tissue Engineering has witnessed an increasing drive toward clinical translation of breakthrough technologies. However, the progression of promising preclinical data to achieve successful clinical market authorisation remains a bottleneck. One hurdle for progress to the clinic is the transition from small animal research to advanced preclinical studies in large animals to test safety and efficacy of products. Notwithstanding this, to draw meaningful and reliable conclusions from animal experiments it is critical that the species and disease model of choice is relevant to answer the research question as well as the clinical problem. Selecting the most appropriate animal model requires in-depth knowledge of specific species and breeds to ascertain the adequacy of the model and outcome measures that closely mirror the clinical situation. Traditional reductionist approaches in animal experiments, which often do not sufficiently reflect the studied disease, are still the norm and can result in a disconnect in outcomes observed between animal studies and clinical trials. To address these concerns a reconsideration in approach will be required. This should include a stepwise approach using in vitro and ex vivo experiments as well as in silico modeling to minimize the need for in vivo studies for screening and early development studies, followed by large animal models which more closely resemble human disease. Naturally occurring, or spontaneous diseases in large animals remain a largely untapped resource, and given the similarities in pathophysiology to humans they not only allow for studying new treatment strategies but also disease etiology and prevention. Naturally occurring disease models, particularly for longer lived large animal species, allow for studying disorders at an age when the disease is most prevalent. As these diseases are usually also a concern in the chosen veterinary species they would be beneficiaries of newly developed therapies. Improved awareness of the progress in animal models is mutually beneficial for animals, researchers, human and veterinary patients. In this overview we describe advantages and disadvantages of various animal models including domesticated and companion animals used in regenerative medicine and tissue engineering to provide an informed choice of disease-relevant animal models.

Role of animal models in biomedical research: a review

Alternatives of Animal Models for Biomedical Research: a Comprehensive Review of Modern Approaches

Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do

The Importance of Animal Models in Biomedical Research: Current Insights and Applications

Large Mammalian Animal Models of Heart Disease

Future Perspective of Diabetic Animal Models

A Comprehensive Review on Redundancy usage of Animal models in Novel Drug testing

Research('s) Sweet Hearts: Experimental Biomedical Models of Diabetic Cardiomyopathy

Small Mammalian Animal Models of Heart Disease.

A Concise Review of Common Animal Models for the Study of Limb Regeneration.

An Overview Of Valuable Scientific Models For Diabetes Mellitus

Exploring the Use of Animal Models in Craniofacial Regenerative Medicine: A Narrative Review

Experimental animal models for diabetes and its related complications—a review

Perspectives on Animal Models Utilized for the Research and Development of Regenerative Therapies for Articular Cartilage

The Sheep as a Large Animal Model for the Investigation and Treatment of Human Disorders

Review on In-vitro Techniques and In-vivo Animals Models for Screening Diabetes and Diabetic Complications

Animal Models of Kidney Disease: Challenges and Perspectives

Animal Models for Cardiovascular Research

Non-Mouse Models of Atherosclerosis: Approaches to Exploring the Translational Potential of New Therapies

Animal models of Alzheimer's disease and drug development

Current advancement in the preclinical models used for the assessment of diabetic neuropathy